Storia in 1 fonti

Exclusive: Acceleron leaders and Westlake jumpstart new IPF biotech

On Tuesday, Oorja Bio launched with a $30 million Series A round all from Westlake BioPartners to study a new treatment for idiopathic pulmonary fibrosis.

Raccontata da

endpoints.news

martedì 19 maggio 2026·endpoints.news
Exclusive: Acceleron leaders and Westlake jumpstart new IPF biotech
On Tuesday, Oorja Bio launched with a $30 million Series A round all from Westlake BioPartners to study a new treatment for idiopathic pulmonary fibrosis.